EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists

Constance H Fung, Cathy Alessi, Jennifer L Martin, Karen Josephson, Lara Kierlin, Joseph M Dzierzewski, Alison A Moore, M Safwan Badr, Michelle Zeidler, Monica Kelly, Jason P Smith, Ian A Cook und 7 weitere

JAMA Internal Medicine · 01.12.2024 · 184 (12) · 1448

DOI: 10.1001/jamainternmed.2024.5020 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.12.2024. Verfasst von Constance H Fung und 18 weiteren Autor:innen. Beteiligte Einrichtung: Geriatric, Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Cognitive Behavioral Therapy, GABA-A Receptor Agonists. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, HSRD VA, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Placebo effects are commonly observed in benzodiazepine receptor agonist hypnotic clinical trials. Clinical guidelines recommend discontinuing benzodiazepine receptor agonist hypnotics (particularly in older adults) and administering cognitive behavioral therapy for insomnia (CBTI) as first-line therapy for insomnia. It is unknown whether a novel intervention that masks the daily dose of benzodiazepine receptor agonist during tapering and augments CBTI with novel cognitive and behavioral exercises targeting placebo effect mechanisms improves benzodiazepine receptor agonist discontinuation.

Objective

To compare a masked benzodiazepine receptor agonist taper plus augmented CBTI vs an unmasked taper plus standard CBTI. Design, Setting, and Participants This randomized clinical trial conducted at an academic medical center and a Department of Veterans Affairs medical center included adults aged 55 years or older who had used lorazepam, alprazolam, clonazepam, temazepam, and/or zolpidem for current or prior insomnia, at doses of less than 8-mg diazepam–equivalent 2 or more nights per week for at least 3 months. Data were collected between December 2018 and November 2023. Data analyses were conducted between November 2023 and July 2024.

Interventions

Masked taper plus cognitive behavioral therapy-augmented program (MTcap); standard CBTI plus supervised (unmasked) gradual taper (SGT). Main Outcomes and Measures The primary efficacy outcome was percentage achieving benzodiazepine receptor agonist discontinuation 6 months after treatment ended (6-month; intention-to-treat) measured with 7-day self-reported medication logs and for a subset, urine tests. Secondary outcomes were Insomnia Severity Index scores at 1 week posttreatment and 6 months posttreatment, percentage of participants that have discontinued benzodiazepine receptor agonist use at 1 week posttreatment, and benzodiazepine receptor agonist dose and the Dysfunctional Beliefs About Sleep-Medication subscale at 1 week and 6 months posttreatment.

Results

Of 338 participants who underwent in-depth screening, 188 participants (mean [SD] age, 69.8 [8.3] years, 123 male [65.4%] and 65 female [35.6%]) were randomly assigned to MTcap (n = 92) or SGT (n = 96). Compared with SGT, MTcap resulted in greater benzodiazepine receptor agonist discontinuation at 6 months (MTcap = 64 [73.4%], SGT = 52 [58.6%]; odds ratio [OR], 1.95; 95% CI 1.03-3.70; P = .04) and 1 week posttreatment (MTcap = 76 [88.4%], SGT = 62 [67.4%]; OR, 3.68; 95% CI, 1.67-8.12; P = .001) and reduced frequency of benzodiazepine receptor agonist use (nights/week) at 1 week posttreatment (−1.31; 95% CI, −2.05 to −0.57; P < .001). Insomnia Severity Index improved with no significant between-group difference at follow-up (baseline to 1 week posttreatment, 1.38; P = .16; baseline to 6 months, 0.16; P = .88). Conclusions and Relevance This randomized clinical trial found that a program combining masked tapering with novel cognitive and behavioral exercises targeting placebo mechanisms improved the percentage of long-term benzodiazepine receptor agonist discontinuation compared with standard CBTI plus an unmasked taper. Trial Registration ClinicalTrials.gov Identifier: NCT03687086

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Initiation and Maintenance DisordersCognitive Behavioral TherapyGABA-A Receptor AgonistsHumansMaleFemaleMiddle AgedAgedBenzodiazepinesDrug TaperingLorazepamHypnotics and SedativesZolpidemAlprazolamClonazepam

Substanzen

GABA-A Receptor AgonistsBenzodiazepinesLorazepamHypnotics and SedativesZolpidemAlprazolamClonazepam

Autor:innen und Institutionen

  • Geriatric, Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California.
  • Department of Medicine, University of California, Los Angeles.
  • Northwest Sleep and Behavior, Nashville, Tennessee.
  • National Sleep Foundation, Washington, DC.
  • Department of Medicine, University of California, San Diego, La Jolla.
  • Department of Internal Medicine, Wayne State University, Detroit, Michigan.

Förderung

  • NIA NIH HHS
  • HSRD VA
  • NHLBI NIH HHS

Zitieren

APA

Fung, C. H., Alessi, C., Martin, J. L., Josephson, K., Kierlin, L., Dzierzewski, J. M., Moore, A. A., Badr, M. S., Zeidler, M., Kelly, M., Smith, J. P., Cook, I. A., Der-Mcleod, E., Ghadimi, S., Naeem, S., Partch, L., Guzman, A., Grinberg, A., & Mitchell, M. (2024). Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists. JAMA Internal Medicine, 184(12), 1448. https://doi.org/10.1001/jamainternmed.2024.5020

Vancouver

Fung CH, Alessi C, Martin JL, Josephson K, Kierlin L, Dzierzewski JM, et al. Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists. JAMA Internal Medicine. 2024;184(12):1448. doi:10.1001/jamainternmed.2024.5020

BibTeX
@article{Fung2024,
  author = {Fung, Constance H and Alessi, Cathy and Martin, Jennifer L and Josephson, Karen and Kierlin, Lara and Dzierzewski, Joseph M and Moore, Alison A and Badr, M Safwan and Zeidler, Michelle and Kelly, Monica and Smith, Jason P and Cook, Ian A and Der-Mcleod, Erin and Ghadimi, Sara and Naeem, Saadia and Partch, Lisa and Guzman, Andrew and Grinberg, Austin and Mitchell, Michael},
  title = {Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists},
  journal = {JAMA Internal Medicine},
  year = {2024},
  volume = {184},
  number = {12},
  pages = {1448},
  doi = {10.1001/jamainternmed.2024.5020}
}
Kostenlos starten →